01 1Cipla
01 1ESCITALOPRAM OXALATE USP
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2021-10-05
Pay. Date : 2021-09-30
DMF Number : 16636
Submission : 2003-06-12
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ESCITALOPRAM OXALATE USP, with a corresponding US DMF Number 16636.
Remarkably, this DMF maintains an Active status since its submission on June 12, 2003, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 05, 2021, and payment made on September 30, 2021, indicating their dedication to facilitating drug approvals, Categorized as Type II
